CytoSorbents Names Thomas Shannon New Vice President of Marketing
CytoSorbents Corporation (NASDAQ: CTSO), known for its innovative medical technologies that address life-threatening conditions in critical care and cardiac surgery, has announced the strategic appointment of Thomas Shannon as Vice President of Marketing for its North American operations. With his extensive background in global strategic marketing and a focus on blood purification, Shannon is expected to lead the company’s marketing efforts for their cutting-edge DrugSorb™-ATR product.
Thrive with Expertise: Thomas Shannon's Background
Thomas Shannon joins the CytoSorbents team with an impressive 25-year history in commercializing groundbreaking technologies for cardiovascular surgery. His previous leadership roles include key positions at Genesee Biomedical, where he was instrumental in cardiac valve innovations, and at Fresenius Medical Care, where he spearheaded the launch of pioneering ECMO life support devices. Shannon’s adeptness in managing large-scale product distributions and strategic market expansions has redefined success for these organizations, and now he brings this wealth of experience to CytoSorbents.
Leadership Vision for DrugSorb™-ATR
In his new role, Shannon is set to champion the marketing strategies for DrugSorb™-ATR, a medical device that aims to mitigate perioperative bleeding in patients undergoing coronary artery bypass graft (CABG) surgery while on the antithrombotic medication Brilinta®. Dr. Phillip Chan, CEO of CytoSorbents, expressed enthusiasm for Shannon's appointment, emphasizing the critical need for innovative solutions that ensure patient safety and surgical success.
The Challenge of Perioperative Bleeding
Perioperative bleeding presents a significant risk during CABG surgeries, often exacerbated by blood-thinning agents like Brilinta®. The DrugSorb™-ATR seeks to address this challenge head-on by effectively removing these blood thinners during and after surgery, potentially averting serious complications. The company continues to work closely with regulatory bodies to advance its marketing applications, with anticipations of decisions pending within a strategic timeline.
A Focus on Patient Safety and Innovation
Shannon's professional journey as a cardiovascular perfusionist positions him uniquely to understand the nuances of surgical procedures involving blood thinners. He articulates a clear vision for the innovative role DrugSorb-ATR could play in improving outcomes for both patients and healthcare providers. His commitment to ensuring straightforward access to this technology underscores CytoSorbents’ mission of enhancing patient care.
CytoSorbents' Position within the Industry
CytoSorbents continues to solidify its leadership role in blood purification technologies, utilizing advanced polymer bead technology to remove harmful substances from blood. These innovative solutions not only focus on the critical removal of blood thinners but also target inflammatory agents linked to various life-threatening conditions such as sepsis and acute liver failure. Expanding on their existing offerings with the DrugSorb-ATR is anticipated to elevate their impact in the medical field.
Future Developments and Strategic Goals
As CytoSorbents navigates through regulatory landscapes, Shannon’s appointment sends a clear message of confidence in the company’s innovative directions. Alongside their proprietary technology, the company is poised to elevate marketing initiatives, develop new applications, and maintain a steadfast focus on the commercialization of vital health solutions that save lives.
Frequently Asked Questions
Who is Thomas Shannon?
Thomas Shannon is the newly appointed Vice President of Marketing for CytoSorbents Corporation, bringing over 25 years of strategic marketing experience in medical devices.
What is DrugSorb™-ATR?
DrugSorb™-ATR is an investigational medical device aimed at reducing perioperative bleeding during surgeries for patients taking blood thinners such as Brilinta®.
What role does CytoSorbents play in medical technology?
CytoSorbents specializes in blood purification technology, developing products that address critical health situations in intensive care and cardiac surgery.
When might DrugSorb™-ATR receive regulatory approval?
Regulatory decisions regarding DrugSorb™-ATR are expected in the coming years, as the FDA and Health Canada continue their reviews of the marketing applications.
How does Thomas Shannon's experience benefit CytoSorbents?
Shannon's extensive background in cardiovascular technologies and product commercialization will facilitate CytoSorbents' marketing strategies and operational growth.
